The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | When will the daratumumab triplet combination be approved for multiple myeloma?
Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. Daratumumab is approved as a single agent by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). According to Dr Palumbo, the submission for the three agent submission will be started and it should be available within 12-18 months.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
